ReviewBBA advances2025
Best evidence linking the extracellular factor TGF-β to cancer-associated alternative splicing programs.
Review in BBA advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cancer Stem Cells in Colorectal Cancer: From Molecular Mechanisms to Diagnosis, Prognosis and Therapy Implications.Cancers · 2026Review
- Splicing isoforms associated with TGFβ-induced myofibroblast activation.BMC molecular and cell biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alternative splicing is a mechanism by which several RNA transcripts can be created from one gene. Splicing factors are RNA binding proteins recognizing cis-acting sequences that positively or negatively influence the splicing decision based on their relative position to the splice site and identity. However, few studies have focused on the regulation of splicing factors, and even less on the regulation of alternative splicing from extracellular factors. Transforming growth factor beta 1 (TGF-β) is a well study extracellular factors regulating multiple cancer-associated cell phenotype (apoptosis, epithelial to mesenchymal transition, angiogenesis, differentiation into cancer-associated fibroblasts) in a cell type-dependent manner. Intriguingly, there is examples of alternative splicing variants and/or their regulatory splicing factors influencing each of these hallmarks in vitro. Here, we provide the best evidence suggesting that TGF-β may drive cancer-associated alternative splicing programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.